Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2008-01-24
2009-08-11
Saeed, Kamal A (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C544S151000
Reexamination Certificate
active
07572791
ABSTRACT:
Morpholino-substituted pyridopyrimidine, quinolone, and benzopyranone derivatives inhibit phosphoinositide (PI) 3-kinase, an enzyme that regulates platelet-adhesion processes. As a consequence, the compounds in question have anti-thrombotic activity, as well as other pharmaceutical properties. The compounds claimed are represented by formula (I), (II) and (III). PI 3-kinase generates 3-phosphorylated PI second messengers which stimulate platelet adhesion under blood-flow conditions. Because platelet adhesion is a necessary step in the formation of a thrombus, inhibition by these compounds of PI 3-kinase under such conditions inhibits or prevents thrombus formation. The compounds are useful in treating PI 3-kinase-dependent conditions including cardiovascular diseases such as coronary artery occlusion, stroke, acute coronary syndrome, acute myocardial infarction, vascular restenosis, atherosclerosis, and unstable angina; respiratory diseases such as asthma, chronic obstructive pulmonary diseases (COPD), and bronchitis; inflammatory disorders; neoplasms including cancers such as glioma, prostate cancer, small cell lung cancer, and breast cancer; and diseases linked to disordered white blood cell function, such as autoimmune and inflammatory diseases.
REFERENCES:
patent: 5703075 (1997-12-01), Gammill et al.
patent: 90/06921 (1990-06-01), None
patent: 91-19707 (1991-12-01), None
Benjamin et al., “2-Aminochromones block human platelet aggregation by inhibiting cyclic AMP-dependent phosphodiesterase leading to reduced platelet phospholipase C activity,” Journal of Pharmacology and Experimental Therapeutics (1993) 265(1):457-462.
Di Braccio et al., “1,2-Fused pyrimidines VII. 3-(Dialkylamino)-1H-pyrimido[1,2-a]quinolin-1-ones and 2-(dialkylamino)-4H-pyrimido[2,1-a]isoquinolin-4-ones as antiplatelet compounds,” European Journal of Medicinal Chemistry (1995) 30(1):27-38.
Cho et al., “Effects of Inclusion Complexation on the Transepithelial Transport of a Lipophilic Substance,” Pharmaceutical Research (1995) 12(4):560-564.
Morris et al., “A novel synthesis of 2-aminochromones via phosgeniminium salts,” Journal of Organic Chemistry (1992) 57(24):6502-6508.
Morris et al., “Synthesis and biological evaluation of antiplatelet 2-aminochromones,” Journal of Medicinal Chemistry (1993) 36(14):2026-2032.
Morris et al., “Synthesis and biological activity of a potent antiplatelet 7-aminofurochromone,” Bioorganic & Medicinal Chemistry Letters (1994) 4(21):2621-2626.
Morris et al., “A Cyclodehydration Route to 2-Aminochromones,” Synthetic Communications (1994) 24(6):849-858.
Vlahos et al., “Phosphatidylinositol 3-kinase, 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one (LY294002),” Journal of Biological Chemistry (1994) 269(7):5241-5248.
Database crossfire beilstein 'Online! Beilstein Institut zur Forderung der Chemischen Wissenchaften, Frankfurt am Main, DE; Database Accession No. BRN 1077329 XP002231193; Abstract, Ingalis, E.A.; Popp, F.D. Journal of Heterocyclic Chemistry (1967) 4:523-526.
Chiosis et al., “LY294002-geldanamycin heterodimers as selective inhibitors of the P13K and P13K-related family,” Bioorganic & Medicinal Chemistry Letters (2001) 11:909-913.
Buchmann et al., “Synthesis in the quinoline series. IV. 2, 4-disubstituted quinoline derivatives,” Journal of the American Chemical Society (1942) 64:1357-1360.
Sosnovskikh et al., “2-polyfluoroalkylchromones 6. Synthesis of substituted 2-morpholino-2-trifluromethylchroman-4-ones,” Russian Chemical Bulletin (2001) (3):434-436.
Jackson Shaun
Kenche Vijaya
Parbaharan Hishani
Robertson Alan D.
Thompson Phil
AstraZeneca AB
Pepper Hamilton LLP
Saeed Kamal A
LandOfFree
Therapeutic morpholino-substituted compounds does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Therapeutic morpholino-substituted compounds, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Therapeutic morpholino-substituted compounds will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4056468